Abstract: The present invention provide phenoxathiin compounds useful in the prophylaxis and treatment of mental disorders, such as depression. The present invention also provides a method for treating a mammal having depression, anxiety or other conditions responsive to inhibition of MAO-A. A method of preparing the compounds of the present invention is also provided.

Abstract: 1-Ethylphenoxathiin 10,10-dioxide (I) ##STR1## inhibits monoamine oxidase-A and is useful in the treatment of disorders such as depression.

Abstract: Compounds of formula (I) ##STR1## wherein n is 0, 1 or 2;one or R.sup.1 and R.sup.2 is hydrogen and the other is selected from carbamoyl, N-C.sub.1-4 alkylcarbamoyl, N,N-di-C.sub.1-4 alkylcarbamoyl, carbamimidoyl, N.sup.1 -C.sub.1-4 alkylcarbamimidoyl, N.sup.2 -C.sub.1-4 alkylcarbamimidoyl, N.sup.1 -C.sub.1-4 alkyl-N.sup.2 -C.sub.1-4 alkylcarbamimidoyl, N.sup.1,N.sup.1 -di-C.sub.1-4 alkylcarbamimidoyl, N.sup.1,N.sup.1 -di-C.sub.1-4 alkyl-N.sup.2 -C.sub.1-4 alkylcarbamimidoyl and imidazolin-2-yl (optionally substituted by one or more C.sub.1-4 alkyl groups); andR.sup.3 is selected from hydrogen, saturated and unsaturated aliphatic hydocarbon moieties containing from 1 to 4 carbon atoms, groups OR.sup.4 (where R.sup.4 is selected from hydrogen and saturated and unsaturated aliphatic hydrocarbon moieties containing from 1 to 4 carbon atoms), halo, groups of formula--NR.sup.5 R.sup.6 (where R.sup.5 and R.sup.6 are independently selected from hydrogen, C.sub.1-4 alkyl and hydroxy C.sub.

Abstract: 3-N-methylcarbamoylthioxanthen-9-one 10,10-dioxide of formula (I) ##STR1## is an inhibitor of monoamine oxidase-A, and is therefore useful in the prophylaxis and treatment of certain mental disorders such as depression.

Abstract: A method of inhibiting monoamine oxidase-A in a mammal such as man, comprising administration to said mammal of an effective amount of a compound of formula (I') or a physiologically acceptable salt, or a pro-drug or metabolite thereof.In formula (I') ##STR1## n is 0, 1 or 2; one of R.sup.1 and R.sup.2 is hydrogen and the other is a tetrazol-5-yl group optionally substituted by one or more C.sub.1-4 alkyl groups; andR.sup.3 is selected from hydrogen, saturated and unsaturated aliphatic hydrocarbon moieties containing from 1 to 4 carbon atoms, groups OR.sup.4 (where R.sup.4 is selected from hydrogen and saturated and unsaturated aliphatic hydrocarbon moieties containing from 1 to 4 carbon atoms), halo, groups of formula --NR.sup.5 R.sup.6 (where R.sup.5 and R.sup.6 are independently selected from hydrogen C.sub.1-4 alkyl and hydroxy C.sub.1-4 alkyl, provided that the total number of carbona atoms in R.sup.5 and R.sup.6 does not exceed 4), amino C.sub.1-4 alkylamino and morpholino.

Abstract: This invention is directed to a carbazole compound 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, its salts, especially pharmaceutically acceptable salts, and solvates such as hydrates, alcoholates of the salts thereof as well as pharmaceutical compositions containing same which are useful in treating aggression and/or psychoses in humans.

Abstract: Diphenylethers of the formula: ##STR1## their synthesis, formulations containing them, methods of making such formulations, and their use in the treatment of liver fluke infections in mammals.